Using Biotechnology to Slow Down Alzheimer's Symptoms

So, this is the path that Axovant pursued for intepirdine. As of late August 2017, hopes were still high that the Axovant late stage clinical trial would yield promising results, signaling a positive change for the Alzheimer’s community. Considering that it’s been over a decade since any drugs have made it past the clinical trial stage, patients and physicians alike are eager for new, better treatments to become available. Still, people were aware that Axovant was not a “miracle drug,” and certainly not a cure. The goal was that that Axovant could potentially push back the timeline of the disease.